Breast Ductal Carcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: BRS099 MIFTS: 63	Breast Ductal Carcinoma Categories: Cancer diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Breast Ductal Carcinoma

MalaCards integrated aliases for Breast Ductal Carcinoma:

Name: Breast Ductal Carcinoma ¹¹ ¹⁴

Ductal Breast Carcinoma ⁵³ ⁵ ⁷¹

Ductal Carcinoma ⁷¹ ⁷⁵

Mammary Ductal Carcinoma ⁷¹

Carcinoma, Ductal ⁴³

Duct Carcinoma ¹¹

Classifications:

MalaCards categories:
Global: Cancer diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹¹ DOID:3007

MeSH ⁴³ D044584

SNOMED-CT ⁶⁸ 82711006

UMLS ⁷¹ C0021367 C1176475 C1527349

Sources

Summaries for Breast Ductal Carcinoma

Disease Ontology: ¹¹ A breast carcinoma that derives from the lining of milk ducts.

MalaCards based summary: Breast Ductal Carcinoma, also known as ductal breast carcinoma, is related to bile duct cancer and intrahepatic cholangiocarcinoma. An important gene associated with Breast Ductal Carcinoma is RAD54L (RAD54 Like), and among its related pathways/superpathways are Signal Transduction and ERK Signaling. The drugs Ropivacaine and Ondansetron have been mentioned in the context of this disorder. Affiliated tissues include breast, salivary gland and lymph node, and related phenotypes are Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) and Increased cell death in HCT116 cells

Wikipedia: ⁷⁵ Ductal carcinoma is a type of tumor that primarily presents in the ducts of a... more...

Sources

Related Diseases for Breast Ductal Carcinoma

Diseases related to Breast Ductal Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 866)

#	Related Disease	Score	Top Affiliating Genes
1	bile duct cancer	32.8	TP53 ERBB2 EGFR CTNNB1 CDH1 CCND1
2	intrahepatic cholangiocarcinoma	32.4	TP53 ERBB2 EGFR CTNNB1
3	breast cystic hypersecretory carcinoma	32.3	PGR ESR1 ERBB2
4	sebaceous breast carcinoma	32.3	PIP ERBB2
5	bile duct adenocarcinoma	32.1	TP53 EGFR CTNNB1 CDH1
6	cholangiocarcinoma	32.1	TP53 TFF1 KRT8 ERBB2 EGFR CTNNB1
7	ductal carcinoma in situ	31.7	TP53 PIP PGR KRT8 ESR1 ERBB2
8	pleomorphic adenoma	31.5	TP53 ERBB2 CTNNB1
9	breast cancer	31.3	ZFAS1 VEGFD TP53 TFF1 RAD54L PIP
10	adenoma	31.3	TP53 MKI67 CTNNB1 CDH1 CCND1 BCL2
11	adenocarcinoma	31.2	VEGFD TP53 ERBB2 EGFR CTNNB1 CDH1
12	salivary gland carcinoma	31.2	TP53 PIP ERBB2 EGFR
13	breast malignant phyllodes tumor	31.1	TP53 PGR ESR1 ERBB2 EGFR
14	transitional cell carcinoma	31.0	TP53 NME1 MKI67 ERBB2 EGFR CDH1
15	papillary adenocarcinoma	31.0	TP53 PIP NME1 ERBB2 BRCA1
16	pleomorphic adenoma carcinoma	31.0	TP53 ERBB2
17	cystadenocarcinoma	31.0	TP53 PGR BRCA1 BCL2
18	tubular adenocarcinoma	31.0	PGR ESR1 ERBB2 CTSD CTNNB1 CDH1
19	mucoepidermoid carcinoma	31.0	KRT8 EGFR CDH3 CDH1
20	renal cell carcinoma, papillary, 1	30.9	TP53 ERBB2 EGFR CDH1
21	sporadic breast cancer	30.8	TP53 PGR ESR1 ERBB2 BRCA1
22	comedo carcinoma	30.8	TP53 PGR ESR1 ERBB2
23	microglandular adenosis	30.8	PIP PGR ESR1 ERBB2 CTSD
24	leiomyosarcoma	30.8	TP53 PGR ESR1 CCND1 BRCA1 BCL2
25	cholecystitis	30.7	TP53 TFF1 EGFR CDH1
26	papillary carcinoma	30.7	NME1 MKI67 ESR1 ERBB2 CDH1
27	inherited cancer-predisposing syndrome	30.7	TP53 EGFR CDH1 BRCA1
28	bap1 tumor predisposition syndrome	30.7	TP53 EGFR CDH1 BRCA1
29	thyroid gland follicular carcinoma	30.7	TP53 CTNNB1 CDH1 CCND1
30	leukemia, chronic lymphocytic	30.7	TP53 ERBB2 EGFR CTNNB1 CCND1 BCL2
31	mucinous adenocarcinoma	30.7	TP53 ERBB2 EGFR CTNNB1
32	hereditary breast cancer	30.7	RAD54L CDH1 BRCA1
33	skin squamous cell carcinoma	30.7	TP53 ERBB2 EGFR CTNNB1 CDH1 CCND1
34	melanoma	30.6	TP53 NME1 MKI67 CTNNB1 CDH3 CDH1
35	diffuse gastric and lobular breast cancer syndrome	30.6	TP53 ERBB2 CTNNB1 CDH1 BRCA1
36	hypertrophy of breast	30.6	TP53 PGR ESR1 ERBB2 EGFR BRCA1
37	gallbladder disease	30.6	TP53 ERBB2 EGFR CTNNB1 CDH1 CCND1
38	breast adenoid cystic carcinoma	30.6	PGR ESR1 ERBB2
39	vulva cancer	30.6	TP53 PIP ERBB2 EGFR CCND1
40	hereditary breast ovarian cancer syndrome	30.6	TP53 RAD54L PGR ESR1 ERBB2 EGFR
41	breast metaplastic carcinoma	30.6	TP53 PGR ESR1 ERBB2
42	mammary paget's disease	30.6	PIP PGR ESR1 ERBB2
43	carcinosarcoma	30.6	TP53 PGR ERBB2 EGFR CTNNB1 CDH1
44	breast papillary carcinoma	30.5	PIP PGR ESR1 ERBB2
45	linitis plastica	30.5	PIP PGR ERBB2 CDH1
46	benign breast phyllodes tumor	30.5	PGR MKI67 ESR1
47	neuroendocrine carcinoma	30.5	PGR ESR1 CDH1
48	gynecomastia	30.5	PGR ESR1 ERBB2
49	esophagus squamous cell carcinoma	30.5	EGFR CTNNB1 CCND1
50	squamous cell carcinoma	30.5	TP53 NME1 MKI67 ERBB2 EGFR CTNNB1

Graphical network of the top 20 diseases related to Breast Ductal Carcinoma:

Sources

Symptoms & Phenotypes for Breast Ductal Carcinoma

GenomeRNAi Phenotypes related to Breast Ductal Carcinoma according to GeneCards Suite gene sharing:

²⁵

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435)	GR00104-A-0	9.35	CCND1 ESR1 MKI67 PIP VEGFD
2	Increased cell death in HCT116 cells	GR00103-A-0	8.85	CTNNB1
3	Decreased viability in pancreas lineage	GR00235-A	8.8	CCND1 PGR TP53

MGI Mouse Phenotypes related to Breast Ductal Carcinoma:

⁴⁵ (show all 17)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	neoplasm	MP:0002006	10.41	BCL2 BRCA1 CCND1 CDH1 CTNNB1 EGFR
2	homeostasis/metabolism	MP:0005376	10.41	BCL2 BRCA1 CCND1 CDH1 CTNNB1 CTSD
3	growth/size/body region	MP:0005378	10.34	BCL2 BRCA1 CCND1 CDH1 CTNNB1 CTSD
4	endocrine/exocrine gland	MP:0005379	10.32	BCL2 BRCA1 CCND1 CDH1 CDH3 CTNNB1
5	normal	MP:0002873	10.3	BRCA1 CCND1 CDH1 CTNNB1 EGFR ERBB2
6	digestive/alimentary	MP:0005381	10.25	BCL2 BRCA1 CCND1 CDH1 CTNNB1 CTSD
7	cellular	MP:0005384	10.22	BCL2 BRCA1 CCND1 CDH1 CTNNB1 CTSD
8	immune system	MP:0005387	10.2	BCL2 BRCA1 CCND1 CDH1 CTNNB1 CTSD
9	cardiovascular system	MP:0005385	10.18	BCL2 BRCA1 CCND1 CDH1 CTNNB1 EGFR
10	embryo	MP:0005380	10.16	BCL2 BRCA1 CDH1 CTNNB1 EGFR ERBB2
11	muscle	MP:0005369	10.14	BCL2 BRCA1 CTNNB1 EGFR ERBB2 ESR1
12	no phenotypic analysis	MP:0003012	10.09	CDH1 CTNNB1 EGFR ESR1 MKI67 PGR
13	limbs/digits/tail	MP:0005371	10.07	BRCA1 CTNNB1 EGFR ERBB2 ESR1 PGR
14	reproductive system	MP:0005389	10.03	BCL2 BRCA1 CCND1 CDH1 CTNNB1 EGFR
15	hematopoietic system	MP:0005397	9.97	BCL2 BRCA1 CCND1 CTNNB1 CTSD EGFR
16	mortality/aging	MP:0010768	9.83	BCL2 BRCA1 CCND1 CDH1 CTNNB1 CTSD
17	integument	MP:0010771	9.44	BCL2 BRCA1 CCND1 CDH1 CDH3 CTNNB1

Sources

Drugs & Therapeutics for Breast Ductal Carcinoma

Drugs for Breast Ductal Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 231)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Ropivacaine

Approved

Phase 4

84057-95-4

71273 175805

Ondansetron

Approved, Withdrawn

Phase 4

99614-02-5

4595

Sufentanil

Approved, Investigational

Phase 4

56030-54-7

41693

Letrozole

Approved, Investigational

Phase 4

112809-51-5

3902

Dsuvia

Phase 4

Anesthetics, Intravenous

Phase 4

Anesthetics, General

Phase 4

Analgesics, Opioid

Phase 4

Hormones

Phase 4

Estrogens

Phase 4

Estrogen Receptor Antagonists

Phase 4

Estrogen Antagonists

Phase 4

Hormone Antagonists

Phase 4

Aromatase Inhibitors

Phase 4

Goserelin

Approved

Phase 2, Phase 3

65807-02-5

5311128 47725

Vinorelbine

Approved, Investigational

Phase 3

71486-22-1

44424639 60780

Leuprolide

Approved, Investigational

Phase 2, Phase 3

53714-56-0

657181

Oxybutynin

Approved, Investigational

Phase 3

5633-20-5

4634

Tamoxifen

Approved

Phase 3

10540-29-1, 54965-24-1

2733526

Lapatinib

Approved, Investigational

Phase 2, Phase 3

231277-92-2, 388082-78-8

208908

Medroxyprogesterone acetate

Approved, Investigational

Phase 3

520-85-4, 71-58-9

6279 10631

Doxorubicin

Approved, Investigational

Phase 3

23214-92-8

31703

Bevacizumab

Approved, Investigational

Phase 2, Phase 3

216974-75-3

135329020

Docetaxel

Approved, Investigational

Phase 3

114977-28-5

148124

Carboplatin

Approved

Phase 3

41575-94-4

10339178 38904

Atezolizumab

Approved, Investigational

Phase 3

1380723-44-3

Epirubicin

Approved

Phase 3

56420-45-2

41867

Cyclophosphamide

Approved, Investigational

Phase 3

50-18-0, 6055-19-2

2907

Sodium citrate

Approved, Investigational

Phase 3

68-04-2

23431961

Anastrozole

Approved, Investigational

Phase 3

120511-73-1

2187

Exemestane

Approved, Investigational

Phase 3

107868-30-4

60198

Gemcitabine

Approved

Phase 3

95058-81-4, 122111-03-9

60750

Cisplatin

Approved

Phase 3

15663-27-1

2767 5702198 441203

Paclitaxel

Approved, Vet_approved

Phase 3

33069-62-4

36314

Hyaluronic acid

Approved, Vet_approved

Phase 3

9004-61-9

53477741

Citric acid

Approved, Nutraceutical, Vet_approved

Phase 3

77-92-9

311

Neurotransmitter Agents

Phase 3

Parasympatholytics

Phase 3

Mandelic Acids

Phase 3

Muscarinic Antagonists

Phase 3

Cholinergic Antagonists

Phase 3

Cholinergic Agents

Phase 3

Antineoplastic Agents, Hormonal

Phase 3

Estrogen Receptor Modulators

Phase 3

Selective Estrogen Receptor Modulators

Phase 3

Antirheumatic Agents

Phase 3

Estrogens, Conjugated (USP)

Phase 3

Contraceptives, Oral, Hormonal

Phase 3

Contraceptive Agents, Male

Phase 3

Liposomal doxorubicin

Phase 3

Interventional clinical trials:

(show top 50) (show all 270)

#	Name	Status	NCT ID	Phase	Drugs
1	The Ultrasound-guided Multiple-injection Costotransverse Block for Mastectomy and Primary Reconstructive Surgery. A Double Blind, Randomised, Placebo Controlled Trial.	Unknown status	NCT04248179	Phase 4	Ropivacaine injection;Saline 0.9%;Sufentanil and PONV prophylaxis
2	Electronic Xoft Intersociety Brachytherapy Trial	Completed	NCT00742222	Phase 4
3	A Clinical Evaluation Of Adipose Derived Regenerative Cells In The Treatment Of Patients With BrEast Deformities Post Segmental Breast ResecTion (Lumpectomy) With Or Without Radiation ThErapy. A Phase IV Post Market Study.	Completed	NCT00616135	Phase 4
4	Effect of Huaier Granule on Postoperative Adjuvant Treatment for High-risk Early-stage Triple-negative Invasive Ductal Carcinoma: a Prospective, Multicenter, Randomized, Controlled, Open-label Study	Recruiting	NCT04790305	Phase 4	Huaier Granule
5	Association of HSD3B1 Genotype With Response to Preoperative Letrozole Therapy Among Postmenopausal Women With Estrogen-Receptor Positive (ER+) HER2/Neu-Negative (HER2-) Invasive Carcinomas of the Breast	Recruiting	NCT05183828	Phase 4	Letrozole
6	Interstitial Brachytherapy Alone Versus External Beam Radiation Therapy After Breast Conserving Surgery for Low-risk Invasive Carcinoma and Low-risk Ductal Carcinoma in Situ (DCIS) of the Female Breast	Unknown status	NCT00402519	Phase 3
7	A Randomized Phase III Study to Investigate the Efficacy and Safety of Docetaxel + Capecitabine vs. Vinorelbine + Capecitabine Followed by Capecitabine Alone as 1st Therapy on Locally Advanced and Metastatic Breast Cancer Patients.	Unknown status	NCT01126138	Phase 3	Vinorelbine plus Capecitabine for 6 cycles, followed by Capecitabine;Docetaxel plus Capecitabine for 6 cycles, followed by Capecitabine
8	A Prospective, Randomized, Open-label Comparison of Preoperative Weekly Paclitaxel and Cisplatin With or Without Endocrine Therapy in Patients With Operable Hormone Receptor Positive and Triple Negative Locally Advanced Breast Cancer	Unknown status	NCT02221999	Phase 2, Phase 3	Paclitaxel;Cisplatin;Gonadotropin-releasing hormone agonist;Letrozole
9	A Randomized Phase III Trial of Comparing Combination Administration of Paclitaxel and Cisplatin Versus CEF as Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy	Unknown status	NCT02879513	Phase 3	Paclitaxel;Cisplatin;Epirubicin;Cyclophosphamide;5-fluoruracil
10	A Phase III, Double-Blind, Controlled Trial of Oxybutynin in the Management of Hot Flashes	Completed	NCT02961790	Phase 3	Oxybutynin Chloride
11	A Phase III Prospective, Randomized, Double-Blind Clinical Trial of Hormone Replacement Therapy In Postmenopausal Women With A History Of Node-Negative Or Ductal Carcinoma In Situ Who Are Receiving Adjuvant Tamoxifen	Completed	NCT00026286	Phase 3	conjugated estrogens;medroxyprogesterone
12	Evaluation of the Diagnostic Performance of MRI±Biopsy to Optimize Resection of Ductal Carcinoma In Situ (DCIS) Breast Cancer	Completed	NCT01112254	Phase 3
13	A Clinical Trial Comparing Anastrozole With Tamoxifen in Postmenopausal Patients With Ductal Carcinoma in Situ (DCIS) Undergoing Lumpectomy With Radiation Therapy	Completed	NCT00053898	Phase 3	anastrozole;tamoxifen citrate
14	Evaluation of a New Intraoperative Gamma Camera for the Sentinel Lymph Node Procedure in Breast Cancer	Completed	NCT00757302	Phase 3
15	Conservative Surgery With or Without Axillary Lymphnode Removal in Treating Women With T1N0 Breast Cancer	Completed	NCT01508546	Phase 3
16	A Randomized Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)	Completed	NCT02125344	Phase 3	non-pegylated liposomal doxorubicin;Carboplatin;Paclitaxel;Epirubicin;Cyclophosphamide;Pertuzumab;Trastuzumab;Ferric carboxymaltose
17	CirCe01 Study: Evaluation of the Use of Circulating Tumour Cells to Guide Chemotherapy From the 3rd Line of Chemotherapy for Metastatic Breast Cancer	Completed	NCT01349842	Phase 3
18	A Randomized Phase III Trial Comparing Nanoparticle-based Paclitaxel With Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Patients With Early Breast Cancer (GeparSepto)	Completed	NCT01583426	Phase 3	nab-Paclitaxel;Paclitaxel
19	A Randomized Phase II Trial Investigating the Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer	Completed	NCT01426880	Phase 2, Phase 3	Carboplatin;background treatment
20	Phase III Trial of Tamoxifen Alone vs. Tamoxifen Plus Radiation Therapy for Good Risk Duct Carcinoma In-Situ (DCIS) of the Female Breast	Completed	NCT00003857	Phase 3	tamoxifen citrate
21	Optimizing Preventative Adjuvant Linac-Based Radiation: The OPAL Trial a Phase II/III Study of Hypofractionated Partial Breast Irradiation in Women With Early Stage Breast Cancer	Recruiting	NCT03077841	Phase 2, Phase 3
22	Radiotherapy Versus Low-Dose Tamoxifen Following Breast Conserving Surgery for Low-Risk and Estrogen Receptor-Positive Ductal Carcinoma in Situ of Breast: an International Open-label Randomized Non-inferiority Trial	Recruiting	NCT04046159	Phase 3	Low-dose tamoxifen
23	Phase 3 Study of Weekly Paclitaxel in Combination With Cisplatin as Adjuvant Chemotherapy for Early Stage Human Epidermal Growth Factor Receptor-2 (HER2) Negative Breast Cancer in High-risk Women	Recruiting	NCT03201861	Phase 3	Paclitaxel, Cisplatin;EC to docetaxel or paclitaxel
24	Testing for Atypia in Random Periareolar Fine Needle Aspiration (RPFNA) Cytology After 12 Months Metformin (1, 1-Dimethylbiguanide Hydrochloride) Chemoprevention Versus Placebo Control in Premenopausal Women	Active, not recruiting	NCT01905046	Phase 3	metformin hydrochloride
25	Neo-Adjuvant Study With the PDL1-directed Antibody in Triple Negative Locally Advanced Breast Cancer Undergoing Treatment With Nab-paclitaxel and Carboplatin	Active, not recruiting	NCT02620280	Phase 3	Carboplatin;Abraxane;MPDL3280A;Anthra
26	Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: A Phase III Study	Active, not recruiting	NCT01953588	Phase 3	fulvestrant;anastrozole
27	RT CHARM: Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation With Breast Reconstruction	Active, not recruiting	NCT03414970	Phase 3
28	A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently With Radiation Therapy and Radiation Therapy Alone for Women With HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy	Active, not recruiting	NCT00769379	Phase 3
29	A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer	Active, not recruiting	NCT01272037	Phase 3	Anastrozole;Exemestane;Letrozole;Systemic Chemotherapy;Tamoxifen Citrate
30	A Randomised Phase III Study of Radiation Doses and Fractionation Schedules in Non-low Risk Ductal Carcinoma In Situ (DCIS) of the Breast	Active, not recruiting	NCT00470236	Phase 3
31	A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers	Active, not recruiting	NCT03768414	Phase 3	Cisplatin;Gemcitabine Hydrochloride;Nab-paclitaxel
32	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Subjects With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma	Terminated	NCT02715804	Phase 3	Placebo;nab-Paclitaxel;Gemcitabine
33	Intra-mammary Distribution of Transdermal Telapristone Versus Oral Telapristone: A Randomized Window Trial in Women Undergoing Mastectomy	Unknown status	NCT02314156	Phase 2	Telapristone Acetate
34	A Phase II Randomized Study Of Intraductal Carboplatin In Women With Ductal Carcinoma In Situ	Unknown status	NCT00669747	Phase 2	Carboplatin i.d. Days 1 & 15;Carboplatin i.d. Day 1; Normal Saline i.d. Day 15;Normal Saline
35	Randomised Trial Testing Observation (No Radiotherapy) Against Radiotherapy In Women With Low-Risk Completely Excised ER Positive Ductal Carcinoma In Situ (DCIS) Of The Breast On Adjuvant Endocrine Therapy	Unknown status	NCT00077168	Phase 2	anastrozole;tamoxifen citrate
36	Resectable Pancreatic Adenocarcinoma Neo-Adjuvant FOLF(IRIN)OX-based CHEmotherapy - A Multicenter, Randomised Phase II Trial (PANACHE01-PRODIGE48 Study)	Unknown status	NCT02959879	Phase 2	FOLFOX neoadjuvant chemotherapy;FOLFIRINOX neoadjuvant chemotherapy;Standard adjuvant chemotherapy;adjuvant chemotherapy
37	A Phase II, Open-label, Single-arm Study of Photodynamic Laser Therapy Using Foscan for Non-curatively-resectable Bile Duct Carcinoma	Unknown status	NCT01016002	Phase 2	Temoporfin
38	A Multicenter Phase II Study of Docosahexaenoic Acid (DHA) in Patients With a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease	Completed	NCT01849250	Phase 2	Docosahexaenoic Acid
39	A Randomized, Placebo-Controlled Phase II Clinical Trial of Omega-3 PUFA Dietary Supplementation in Patients With Stage I-III Breast Carcinoma	Completed	NCT01869764	Phase 2	omega-3 fatty acid
40	Pre-surgical Phase IIb Trial of Transdermal 4-Hydroxytamoxifen vs. Oral Tamoxifen in Women With Ductal Carcinoma in Situ of the Breast	Completed	NCT00952731	Phase 2	oral placebo;afimoxifene;tamoxifen citrate;placebo gel
41	Efficacy and Tolerance of an Ovarian Stimulation Protocol Combining FSH and Degarelix Acetate in Female Candidates for Fertility Preservation Before Chemotherapy for Breast Cancer	Completed	NCT03947151	Phase 2	Degarelix injection(s)
42	A Randomized Trial to Explore the Effect of Oral Omega 3 Fatty Acids on Atrophic Vaginitis in Postmenopausal Breast Cancer Survivors	Completed	NCT02150525	Phase 2
43	Ten Years Results of a Score System to Address Adjuvant Therapies After Breast Conserving Surgery for Ductal Carcinoma in Situ of the Breast.	Completed	NCT03002766	Phase 2
44	Randomized Phase II Biomarker Pilot Trial of Fluvastatin Use in Women With Ductal Carcinoma in Situ (DCIS) or Stage I Breast Cancer	Completed	NCT00416403	Phase 2	fluvastatin sodium
45	Sulforaphane: A Dietary Histone Deacetylase (HDAC) Inhibitor in Ductal Carcinoma in Situ (DCIS)	Completed	NCT00843167	Phase 2
46	MammoSite Radiation Therapy System (RTS) as the Sole Radiation Therapy Technique for Ductal Carcinoma In-Situ (DCIS)	Completed	NCT00586326	Phase 2
47	Primary Hormonal Therapy for Ductal Carcinoma in Situ: Exploration of a Novel Approach to the Clinical Management of Noninvasive Breast Cancer	Completed	NCT00290745	Phase 1, Phase 2	letrozole;tamoxifen citrate
48	A Multicenter, Open-Label Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 (Doxorubicin-EMCH) in Subjects With Advanced or Unresectable Pancreatic Ductal Carcinoma Whose Tumors Have Progressed Following Prior Treatment With Gemcitabine and Fluoropyrimidine-Based Chemotherapy	Completed	NCT01580397	Phase 2	INNO-206
49	Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)	Completed	NCT01439711	Phase 2	letrozole
50	Preventing Invasive Breast Neoplasia With Chloroquine (PINC) Trial	Completed	NCT01023477	Phase 1, Phase 2	Chloroquine Standard Dose (500mg/week);Chloroquine Low Dose (250mg/week)

Search NIH Clinical Center for Breast Ductal Carcinoma

Cochrane evidence based reviews: carcinoma, ductal

Sources

Genetic Tests for Breast Ductal Carcinoma

Sources

Anatomical Context for Breast Ductal Carcinoma

Organs/tissues related to Breast Ductal Carcinoma:

MalaCards : Breast, Salivary Gland, Lymph Node, Liver, Pancreas, Kidney, Prostate

Sources

Publications for Breast Ductal Carcinoma

Articles related to Breast Ductal Carcinoma:

(show top 50) (show all 4631)

#	Title	Authors	PMID	Year
1	Mutations in the RAD54 recombination gene in primary cancers. ⁵	Matsuda M...Kamiya K	10362365	1999
2	Concomitant expression of epithelial-mesenchymal transition biomarkers in breast ductal carcinoma: association with progression. ⁵³ ⁶²	Logullo AF...Brentani MM	20043090	2010
3	E-cadherin expression in estrogen receptor-positive and negative breast carcinomas of postmenopausal women. ⁵³ ⁶²	da Silva BB...Lopes-Costa PV	20349789	2010
4	Interpretation of Pin-1 and VEGF-C expression in breast infiltrating duct carcinoma. ⁵³ ⁶²	Kim BC...Lim SC	19885590	2009
5	A pilot study to assess the feasibility of evaluation of markers of response to chemotherapy at one day & 21 days after first cycle of chemotherapy in carcinoma of breast: a prospective non-randomized observational study. ⁵³ ⁶²	Sharma S...Vijaykumar DK	19331661	2009
6	Interobserver variability and aberrant E-cadherin immunostaining of lobular neoplasia and infiltrating lobular carcinoma. ⁵³ ⁶²	Choi YJ...Riba AK	18587329	2008
7	[Relationship of ezrin protein expression to the carcinogenesis and prognosis of infitrating breast ductal carcinoma]. ⁵³ ⁶²	Ma L...Wang YJ	18788632	2008
8	[Clinicopathologic significance of chromosome 17 polysomy in breast cancer]. ⁵³ ⁶²	Lu YL...Zhao P	18681318	2008
9	Salivary duct carcinoma: a clinical and histologic review with implications for trastuzumab therapy. ⁵³ ⁶²	Nabili V...Head CS	17563907	2007
10	P63 and cytokeratin8/18 expression in breast, atypical ductal hyperplasia, ductal carcinoma in situ and invasive duct carcinoma. ⁵³ ⁶²	Shamloula MM...Saied EM	19190693	2007
11	A mutation in the 5' untranslated region of the BRCA1 gene in sporadic breast cancer causes downregulation of translation efficiency. ⁵³ ⁶²	Wang J...Ma X	17697535	2007
12	Correlation of HER-2/neu protein overexpression with other prognostic and predictive factors in invasive ductal breast cancer. ⁵³ ⁶²	Ivkovic-Kapicl T...Panjkovic M	17708365	2007
13	Promoter hypermethylation of TMS1, BRCA1, ERalpha and PRB in serum and tumor DNA of invasive ductal breast carcinoma patients. ⁵³ ⁶²	Mirza S...Ralhan R	17599361	2007
14	Identification of a basal-like subtype of breast ductal carcinoma in situ. ⁵³ ⁶²	Livasy CA...Millikan RC	17234468	2007
15	An expression signature of syndecan-1 (CD138), E-cadherin and c-met is associated with factors of angiogenesis and lymphangiogenesis in ductal breast carcinoma in situ. ⁵³ ⁶²	Gotte M...Wulfing P	17244359	2007
16	Expression of nm23, MMP-2, TIMP-2 in breast neoplasm in Zhengzhou Center Hospital, China. ⁵³ ⁶²	Peihong S...Perry F	17642161	2007
17	CD44 expression and axillary lymph node metastasis in infiltrating ductal carcinoma of the breast. ⁵³ ⁶²	Looi LM...Yip CH	18376796	2006
18	E-cadherin immunohistochemical expression as a prognostic factor in infiltrating ductal carcinoma of the breast: a systematic review and meta-analysis. ⁵³ ⁶²	Gould Rothberg BE...Bracken MB	16791476	2006
19	Smad4-expression is decreased in breast cancer tissues: a retrospective study. ⁵³ ⁶²	Stuelten CH...Knabbe C	16438724	2006
20	Expression of hypoxia-inducible factor (HIF-1alpha), VEGF-C and VEGF-D in non-invasive and invasive breast ductal carcinomas. ⁵³ ⁶²	Okada K...Ohgi S	16080559	2005
21	Localisation of COX-2 protein is different in breast ductal carcinoma and adjacent non-tumour ductal epithelium. ⁵³ ⁶²	Cejas P...Gonzalez-Baron M	16131446	2005
22	Transient transfection of epidermal growth factor receptor gene into MCF7 breast ductal carcinoma cell line. ⁵³ ⁶²	Alokail MS	15584089	2005
23	PPARgamma expression in breast cancer: clinical value and correlation with ERbeta. ⁵³ ⁶²	Papadaki I...Nakopoulou L	15656884	2005
24	Correlation of KIT and EGFR overexpression with invasive ductal breast carcinoma of the solid-tubular subtype, nuclear grade 3, and mesenchymal or myoepithelial differentiation. ⁵³ ⁶²	Tsuda H...Hiraide H	15649255	2005
25	The prognostic value of p53 and c-erbB-2 expression, proliferative activity and angiogenesis in node-negative breast carcinoma. ⁵³ ⁶²	Erdem O...Gunel N	15850004	2005
26	Alterations of p53, Bcl-2, and hMSH2 protein expression in the normal breast, benign proliferative breast disease, in situ and infiltrating ductal breast carcinomas in the upper Egypt. ⁵³ ⁶²	Hussein MR...Ismael HH	15467428	2004
27	Real-time quantitative PCR of microdissected paraffin-embedded breast carcinoma: an alternative method for HER-2/neu analysis. ⁵³ ⁶²	Gjerdrum LM...Hamilton-Dutoit S	14736826	2004
28	Immunohistochemical status of p53, MDM2, bcl2, bax, and ER in invasive ductal breast carcinoma in Tunisian patients. ⁵³ ⁶²	Baccouche S...Jlidi R	15033823	2003
29	Role of COX-2, VEGF and cyclin D1 in mammary infiltrating duct carcinoma. ⁵³ ⁶²	Lim SC	12883688	2003
30	Hypoxia promotes a dedifferentiated phenotype in ductal breast carcinoma in situ. ⁵³ ⁶²	Helczynska K...Pahlman S	12670886	2003
31	The epithelial-specific ETS transcription factor ESX/ESE-1/Elf-3 modulates breast cancer-associated gene expression. ⁵³ ⁶²	Eckel KL...Gutierrez-Hartmann A	12713734	2003
32	Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients. ⁵³ ⁶²	Honorio S...Latif F	12527916	2003
33	Cell proliferation, nuclear ploidy, and EGFr and HER2/neu tyrosine kinase oncoproteins in infiltrating ductal breast carcinoma. ⁵³ ⁶²	Fernandez Val JF...Sarria R	12419588	2002
34	Significance of E-cadherin/beta-catenin complex and cyclin D1 in breast cancer. ⁵³ ⁶²	Lim SC...Lee MS	12168049	2002
35	The angiogenic and lymphangiogenic factor vascular endothelial growth factor-D exhibits a paracrine mode of action in cancer. ⁵³ ⁶²	Achen MG...Stacker SA	12148568	2002
36	p63 expression in normal, hyperplastic and malignant breast tissues. ⁵³ ⁶²	Wang X...Kakudo K	12185332	2002
37	p53 gene alteration and protein expression in Iranian women with infiltrative ductal breast carcinoma. ⁵³ ⁶²	Pezeshki AM...Ghaderi A	11410327	2001
38	pS2 expression in infiltrating ductal carcinoma of the breast correlates with oestrogen receptor positivity but not with histological grade and lymph node status. ⁵³ ⁶²	Looi LM...Ng MH	11523925	2001
39	The prognostic significance of P-cadherin in infiltrating ductal breast carcinoma. ⁵³ ⁶²	Gamallo C...Palacios J	11454996	2001
40	Expression of p21Waf1, p27Kip1 and cyclin D1 proteins in breast ductal carcinoma in situ: Relation with clinicopathologic characteristics and with p53 expression and estrogen receptor status. ⁵³ ⁶²	Oh YL...Yang JH	11169147	2001
41	Salivary duct carcinoma--a highly aggressive salivary gland tumor with HER-2/neu oncoprotein overexpression. ⁵³ ⁶²	Skalova A...Plank L	11569926	2001
42	Cytokeratin 8 immunostaining pattern and E-cadherin expression distinguish lobular from ductal breast carcinoma. ⁵³ ⁶²	Lehr HA...Gown AM	10941333	2000
43	Adrenocorticotropic hormone and growth factor receptors in breast cancer. ⁵³ ⁶²	Ray A...Sharma BK	11215308	2000
44	Bcl-2 with loss of apoptosis allows accumulation of genetic alterations: a pathway to metastatic progression in human breast cancer. ⁵³ ⁶²	Sierra A...Fabra A	10754491	2000
45	Cyclin D1 overexpression in a model of human breast premalignancy: preferential stimulation of anchorage-independent but not anchorage-dependent growth is associated with increased cdk2 activity. ⁵³ ⁶²	Zhou Q...Steeg PS	10752677	2000
46	Expression of glycodelin in human breast and breast cancer. ⁵³ ⁶²	Kamarainen M...Seppala M	10597188	1999
47	A comparison of the pattern of cathepsin-D expression in fibroadenoma, fibrocystic disease, preinvasive and invasive ductal breast carcinoma. ⁵³ ⁶²	Zheng WQ...Cheah PL	10503271	1999
48	Immunohistochemical co-expression of c-erbb-2/Neu oncoprotein, altered tumour suppressor (p53) protein, EGF-R and EMA in histological subtypes of infiltrating duct carcinoma of the breast. ⁵³ ⁶²	Sharma BK...Gupta S	10641149	1999
49	[Immunohistochemical tumor markers in infiltrating ductal breast carcinoma]. ⁵³ ⁶²	Gallegos M...Duarte I	10030093	1998
50	p53 protein expression in benign and malignant breast lesions. ⁵³ ⁶²	Ioakim-Liossi A...Vaiopoulos G	9684577	1998

Sources

Genes for Breast Ductal Carcinoma

Genes related to Breast Ductal Carcinoma (1 elite genes):

(show top 50) (show all 54)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	RAD54L	RAD54 Like	Protein Coding	402.89	Pathogenic ⁵ DISEASES inferred ¹⁴	10362365
2	ZFAS1	ZNFX1 Antisense RNA 1	RNA Gene	152.97	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴	21460236
3	ERBB2	Erb-B2 Receptor Tyrosine Kinase 2	Protein Coding	36.35	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	1701961 9568187 17708365 (more) 8900371 15569996 8687126 10754491 12713734 15850004 12419588 11569926 8532697 14736826 12481013 16169726 15696127 18681318 17119686 20108215 1350456 16426921 16619488 17940078 17522367 18948375 15279632 20071783 17549359 12438265 10656439 8750531 16969029 16540735 15722788 16681686 15743737 15375487 12607595 7496594 1323096 1977679 19732720 17060931 19414985 11147584 7666587 7687354 16716590 12825853 9870147 1672262 8007712 9563885 10709098 12368191 17347129 9762367 8855985 1348967 20332474 19915523 19886180 19383888 19295274 18296077 19448591 18264744 17563907 17879632 17220672 16969028 16753605 15842638 16979070 16324201 16637512 15998374 15574760 14680497 11893034 11850540 11882907 15799760 11994759 11912139 10396301 1346789 1676930 20037463 19214111 18306351 17549356 16869955 11584314 10759945 10641149 9228251 7910395 8098318 1357006 7911998 1698166 20406831 20306655 19781189 19106577 19106576 18695902 15190415 10678582
4	ESR1	Estrogen Receptor 1	Protein Coding	35.24	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	8744803 11523925 9522973 (more) 20349789 9568187 18982746 11169147 8168185 10606182 10690532 11758715 17522367 17940078 18296077 8806958 1323096 18227734 18508419 7534041 9005143 19642980 9414177 16755106 15131053 12825853 12598915 12532908 12165659 11850804 10816343 9870147 18269781 16425286 15842638 15619212 11578586 11374797 11288957 9664905 10879259 2162679 20495324 20037463 18409153 17143475 16570270 16276696 15736216 15574760 8869993 20495326 8381562 19755043 18839307 19207951 17638621 17123107 16867866 18219900 17599361 16826579 16311245 14747501 11982477 9413224 9360841 1965755 14659136 11374796 20056007 17633393 16596655 16033090 15692763 15375487 11342981 10338072 10226540 16142310 12736568 11994759 11929326 14732176 11096350 11060273 10022453 12168892 11857395 11584314 9893652 8816882 8100443 8098318 2164337 8562164 19781189 19381686 19106577 19106576 18223478 16882697 17234468 7840511 15354746 16682508 16698656 14735188 10709098
5	TP53	Tumor Protein P53	Protein Coding	32.1	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	11410327 10983725 8384406 (more) 8532697 9568187 1746898 9816145 15850004 9301454 10754491 8917421 11169147 8066070 10928110 15467428 9684577 20208478 17119686 16169726 10656439 19836055 8932338 10574259 9870147 12825853 9485035 9788535 8542791 16839413 12607595 11193217 10090408 1323096 18041310 11333292 11276023 11715068 11304577 11147584 9568057 9236923 1684809 17291532 10767354 19719774 9854494 18942291 9779489 10652623 10709098 11261826 12014222 10719727 9269835 7914742 1373310 18936692 17234468 16311351 15138484 12552965 15998374 14680497 15033823 12395898 10623646 9467486 9228251 9216675 8782990 12841678 12402149 12168077 11342981 11175617 14973382 10365096 10226540 8869993 15377846 14567723 10656732 10452507 10030093 7562248 7913368 17923265 16507397 16848860 16033090 15246568 12858214 12736568 12171884 11994759 10928168 9815673 9428925 8944328 8176940 1355662 17549359 17549356 16869955 15717000 16886641 16276696 8758245 8554979 8041120 8312582 8098318 19806450
6	CDH1	Cadherin 1	Protein Coding	31.57	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	16791476 8183909 10941333 (more) 10451483 20043090 20349789 12789915 17244359 7534041 12478484 17649807 12168049 11190811 20078969 12712492 17437014 10398100 20510078 10854942 12879601 18839850 14645693 15363312 8383197 12219785 11439345 11161777 10969774 19751508 18788632 17150092 10402239 9365159 9155715 8567396 19242056 18662704 18397281 16258702 19790246 18794357 18473330 17821836 16287501 16575508 15252316 15074561 14750249 11747235 20388391 17721269 16610682 12861063 18469796 10506713 9422525 18587329 14580257 11857408 11322170 11276001 10759945 15330167 8883410 19893985 18379416 12786888
7	PGR	Progesterone Receptor	Protein Coding	28.58	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	11940423 9586418 15569996 (more) 18982746 1347986 8168185 17522367 18296077 12014222 15375487 1323096 11994759 7906196 7534041 8958553 10094898 10692181 8851103 11062090 11288957 20108215 19781189 19381686 16311351 15131053 12825853 12401835 12165659 16142310 12736568 11825917 7878527 8386929 20037463 18409153 17061047 16276696 19968660 18219900 16826579 16311245 9874456 9413224 9360841 7562248 7981902 20037338 19147189 19201736 9232275 9017447 8917421 7831531 18497053 17985332 16828238 15843292 15108046 11953856 7680194 17638621 12168892 10759945 9893652 18508419 16969029 16540735 15842638 15722790 9414177 7840511 10709098 12412159 16241993 16426921 16682508
8	PIP	Prolactin Induced Protein	Protein Coding	24.34	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	8248106 15569980 18753974
9	EGFR	Epidermal Growth Factor Receptor	Protein Coding	21.45	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	8744803 8532697 12419588 (more) 15584089 18084281 10754491 11758715 17522367 16311351 12825853 10641149 9563885 1698166 11288957 16324201 11260109 8254086 18839307 17440163 16540006 16528377 12736568 12353824 17989321 19201736 15649255 11215308 9870145 10908152 18024331 9891528 19262097 16682508 17234468 16785780
10	CCND1	Cyclin D1	Protein Coding	21.29	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	9413224 11836618 10886733 (more) 15949328 8832554 17940078 12825853 12168049 16341149 12883688 18337623 9664905 8195927 17316413 16517411 10957889 9831206 16848860 11793365 9563877 9212742 16416735 11879554 10752677 19885590 10526005 16311245 11391609 9893652 10719727 9652762 18223478 12532908 11114859
11	VEGFD	Vascular Endothelial Growth Factor D	Protein Coding	20.92	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	15534089 15996865 16080559 (more) 12148568
12	TFF1	Trefoil Factor 1	Protein Coding	20.62	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	11523925 9202892 11060273 (more) 11709137 8385977 15375487 8253523 7647329 18409153 7840511 8855985 11288957
13	CTSD	Cathepsin D	Protein Coding	20.61	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	11940423 18254778 10610231 (more) 8816882 9683294 7906196 17996735 8385566 12400981 10503271 12016391 10845280 18409153 11288957 8758245
14	BCL2	BCL2 Apoptosis Regulator	Protein Coding	20.12	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	17064501 9870147 17372162 (more) 18041310 11994759 11276023 16839413 10767354 9779489 19331661 19781189 9138606 16540735 9815673 19995377 11678802 8917421 16826579 16274043 11291923 16848860 12402149 15467428 8630957 9269835 8900371 18223478 15131053 19645793 10652623
15	MKI67	Marker Of Proliferation Ki-67	Protein Coding	20.12	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	9467486 11289127 16241993 (more) 17549359 10365096 20424617 16507397 16416735 16869955 12165659
16	BRCA1	BRCA1 DNA Repair Associated	Protein Coding	20.04	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	17697535 15728167 10709098 (more) 16241993 10064388 8605099 11072248 9167459 9988281 14506147 12754741 16800895 17599361 11307153 20233467 12375049 9872332 19541683 18400253 11481082 15717000 16537562 17347129 11956301 12552965 15138484 18309013
17	KRT8	Keratin 8	Protein Coding	19.91	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	10941333 19201736 14660278 (more) 16825119
18	CTNNB1	Catenin Beta 1	Protein Coding	19.55	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	11237489 12168049 18337623 (more) 18662704 12879601 18695902 19751508 11825932 15074561 10398100 11793365 9422525 8872147 20043090 10759945
19	CDH3	Cadherin 3	Protein Coding	18.8	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	11454996 7534041 11942571 (more) 12608656 12560394 17123107 14645693
20	NME1	NME/NM23 Nucleoside Diphosphate Kinase 1	Protein Coding	18.33	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	8386774 1714241 17642161 (more) 19781189 18454879 8347849 9042324 8912348
21	MET	MET Proto-Oncogene, Receptor Tyrosine Kinase	Protein Coding	18.15	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	8546209 10590366 20043090 (more) 9024713 10759945 17593080
22	FAP	Fibroblast Activation Protein Alpha	Protein Coding	18	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : localization (show sections)	11241314 9758365 17047060 (more) 14524536
23	AR	Androgen Receptor	Protein Coding	17.96	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	17465263 18508419 8911118 (more) 12910513 17459204 17543076 19201736 18794357 9360841 9467486 15722790
24	KRT19	Keratin 19	Protein Coding	17.79	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	8884352 10908152 10526005 (more) 12670886 7515675
25	VEGFC	Vascular Endothelial Growth Factor C	Protein Coding	16.79	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	19885590 15534089 15996865 (more) 20126999 17425844 16080559
26	CDKN1A	Cyclin Dependent Kinase Inhibitor 1A	Protein Coding	16.35	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	12825853 11345133 8688323
27	BRCA2	BRCA2 DNA Repair Associated	Protein Coding	15.72	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	15728167 15528970 17347129 (more) 19541683 16280055 11307153 9167459 18597679
28	SMAD4	SMAD Family Member 4	Protein Coding	15.28	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	16438724 16627986 15173084 (more) 10980115 15832194 19943940 15154643
29	MUC1	Mucin 1, Cell Surface Associated	Protein Coding	14.97	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	12493022 11420467 10641149 (more) 17650217 10502721 11391575 12015744 16886641 16052519 11496338 20103682 10417690 17593529 10521973 12353144 8384065 9503463
30	THBS1	Thrombospondin 1	Protein Coding	14.97	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	8548120 7680285 7511188 (more) 12461058 12927044 19396698 9012463 12814189
31	TIMP2	TIMP Metallopeptidase Inhibitor 2	Protein Coding	14.78	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	17642161
32	KRT14	Keratin 14	Protein Coding	14.63	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	1384227 17522367 12884041 (more) 10680887 19201736 16698948 7535804 9605010
33	KRT5	Keratin 5	Protein Coding	14.46	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	16241993 17522367 17123107 (more) 19536621
34	ESR2	Estrogen Receptor 2	Protein Coding	14.18	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	15656884 14657709 10690532 (more) 11289127 15867209 10022453 14517838 16322330
35	PLAU	Plasminogen Activator, Urokinase	Protein Coding	14.02	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	11706057 12016391 19082473 (more) 15252843 8569179 8388317
36	CYP19A1	Cytochrome P450 Family 19 Subfamily A Member 1	Protein Coding	13.87	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	8923858 12150452 16322898 (more) 20191218 18256205 20179229 17661084 15242248 18816321 17490137 17618822 16024247 18079323 19782135
37	KRT7	Keratin 7	Protein Coding	13.56	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	20518885 7535804
38	TP63	Tumor Protein P63	Protein Coding	12.94	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	11474290 12502930 16241993 (more) 12704442 12653579 19190693 16258511 12811858 16698948 18206495 12461063 16810311 12884041 12185332 17120733
39	MUC5AC	Mucin 5AC, Oligomeric Mucus/Gel-Forming	Protein Coding	12.68	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	12493022 15235131 8384065 (more) 11420467 16052519 11496338
40	SERPINB5	Serpin Family B Member 5	Protein Coding	12.67	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	12786889 19944674 12425757 (more) 12493023 15256060 16614520
41	MAPK3	Mitogen-Activated Protein Kinase 3	Protein Coding	12.41	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
42	S100A7	S100 Calcium Binding Protein A7	Protein Coding	12.37	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	12855640 15217497 16357139 (more) 15740587 11782356 16082188 8840971
43	SYP	Synaptophysin	Protein Coding	12.32	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	18657193 19126567
44	PTEN	Phosphatase And Tensin Homolog	Protein Coding	12.04	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	15551732 11178110 16020969 (more) 20056007 19212625 16208702 14674989 16341149 16517411 11737885
45	TGFBR2	Transforming Growth Factor Beta Receptor 2	Protein Coding	11.75	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
46	EZR	Ezrin	Protein Coding	11.73	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
47	KRT18	Keratin 18	Protein Coding	11.63	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	18695902 20103682 15102669 (more) 19201736
48	CDKN1B	Cyclin Dependent Kinase Inhibitor 1B	Protein Coding	11.63	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
49	MYH11	Myosin Heavy Chain 11	Protein Coding	11.39	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	15762278
50	MAPK1	Mitogen-Activated Protein Kinase 1	Protein Coding	11.33	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)

Sources

Variations for Breast Ductal Carcinoma

ClinVar genetic disease variations for Breast Ductal Carcinoma:

⁵ (show top 50) (show all 257)

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	Position
1	RAD54L	NM_003579.4(RAD54L):c.973G>A (p.Gly325Arg)	SNV	Pathogenic	6193	rs121908690	GRCh37: 1:46733212-46733212 GRCh38: 1:46267540-46267540
2	overlap with 3 genes	GRCh37/hg19 1p31.3(chr1:67327908-67519596)x3	CN GAIN	Uncertain Significance	221411		GRCh37: 1:67327908-67519596 GRCh38:
3	overlap with 9 genes	GRCh37/hg19 16q11.2-12.1(chr16:46615804-47345238)x1	CN LOSS	Uncertain Significance	221520		GRCh37: 16:46615804-47345238 GRCh38:
4	overlap with 32 genes	chr19:36674305-38652962 complex variant	COMPLEX	Uncertain Significance	221351		GRCh37: 19:36674305-38652962 GRCh38:
5	overlap with 2 genes	GRCh37/hg19 6p22.1(chr6:30029374-30036983)x3	CN GAIN	Uncertain Significance	221454		GRCh37: 6:30029374-30036983 GRCh38:
6	overlap with 13 genes	GRCh37/hg19 17p13.1(chr17:8017865-8135384)x3	CN GAIN	Uncertain Significance	221394		GRCh37: 17:8017865-8135384 GRCh38:
7	HTRA2	NM_013247.5(HTRA2):c.695T>A (p.Leu232Gln)	SNV	Uncertain Significance	221314	rs869025234	GRCh37: 2:74757932-74757932 GRCh38: 2:74530805-74530805
8	overlap with 4 genes	GRCh37/hg19 16p11.2(chr16:29814850-29830976)x4	CN GAIN	Uncertain Significance	221514		GRCh37: 16:29814850-29830976 GRCh38:
9	overlap with 4 genes	GRCh37/hg19 19p13.2(chr19:7682488-7698319)x3	CN GAIN	Uncertain Significance	221540		GRCh37: 19:7682488-7698319 GRCh38:
10	overlap with 4 genes	GRCh37/hg19 3p26.1(chr3:4706901-5216065)x3	CN GAIN	Uncertain Significance	221431		GRCh37: 3:4706901-5216065 GRCh38:
11	overlap with 8 genes	GRCh37/hg19 11q21(chr11:94696615-95528715)x3	CN GAIN	Uncertain Significance	221480		GRCh37: 11:94696615-95528715 GRCh38:
12	overlap with 2 genes	chr20:61880169-61908597 complex variant	COMPLEX	Uncertain Significance	221371		GRCh37: 20:61880169-61908597 GRCh38:
13	overlap with 215 genes	chr1:909238-16736132 complex variant	COMPLEX	Uncertain Significance	221357		GRCh37: 1:909238-16736132 GRCh38:
14	overlap with 2 genes	GRCh38/hg38 16q22.2(chr16:72059151-72063259)x0	CN LOSS	Uncertain Significance	221526		GRCh37: 16:72093050-72097158 GRCh38: 16:72059151-72063259
15	NIPBL	GRCh37/hg19 5p13.2(chr5:37000955-37014827)x4	CN GAIN	Uncertain Significance	221443		GRCh37: 5:37000955-37014827 GRCh38:
16	overlap with 6 genes	GRCh37/hg19 5q12.1(chr5:60240797-61658323)x3	CN GAIN	Uncertain Significance	221383		GRCh37: 5:60240797-61658323 GRCh38:
17	overlap with 4 genes	GRCh37/hg19 2q31.1(chr2:172379152-172803266)x3	CN GAIN	Uncertain Significance	221426		GRCh37: 2:172379152-172803266 GRCh38:
18	overlap with 3 genes	GRCh37/hg19 18q12.2(chr18:33611007-33722860)x4	CN GAIN	Uncertain Significance	221535		GRCh37: 18:33611007-33722860 GRCh38:
19	overlap with 8 genes	GRCh37/hg19 6p22.2-22.1(chr6:26545571-27115102)x3	CN GAIN	Uncertain Significance	221452		GRCh37: 6:26545571-27115102 GRCh38:
20	overlap with 19 genes		COMPLEX	Uncertain Significance	221343		GRCh37: 11:870446-1857751 GRCh38:
21	overlap with 81 genes	chr12:10074776-18800953 complex variant	COMPLEX	Uncertain Significance	221369		GRCh37: 12:10074776-18800953 GRCh38:
22	overlap with 8 genes	GRCh37/hg19 16p12.3(chr16:19083339-19586433)x4	CN GAIN	Uncertain Significance	221512		GRCh37: 16:19083339-19586433 GRCh38:
23	overlap with 10 genes	GRCh37/hg19 12q13.13(chr12:53421635-53645669)x3	CN GAIN	Uncertain Significance	221489		GRCh37: 12:53421635-53645669 GRCh38:
24	overlap with 6 genes	GRCh37/hg19 2q35(chr2:219221864-219423299)x3	CN GAIN	Uncertain Significance	221429		GRCh37: 2:219221864-219423299 GRCh38:
25	overlap with 25 genes	chr20:60885242-61929348 complex variant	COMPLEX	Uncertain Significance	221355		GRCh37: 20:60885242-61929348 GRCh38:
26	overlap with 12 genes	GRCh37/hg19 10p11.22-11.21(chr10:32323692-37520394)x3	CN GAIN	Uncertain Significance	221475		GRCh37: 10:32323692-37520394 GRCh38:
27	overlap with 6 genes	GRCh37/hg19 1p13.2(chr1:113134186-113265713)x3	CN GAIN	Uncertain Significance	221415		GRCh37: 1:113134186-113265713 GRCh38:
28	KNDC1	NM_152643.8(KNDC1):c.2914G>T (p.Glu972Ter)	SNV	Uncertain Significance	221318	rs869025238	GRCh37: 10:135013889-135013889 GRCh38: 10:133200385-133200385
29	overlap with 4 genes	GRCh37/hg19 16p11.2(chr16:31123271-31153163)x4	CN GAIN	Uncertain Significance	221518		GRCh37: 16:31123271-31153163 GRCh38:
30	overlap with 2 genes	GRCh37/hg19 20p12.1(chr20:13714429-13789519)x3	CN GAIN	Uncertain Significance	221544		GRCh37: 20:13714429-13789519 GRCh38:
31	overlap with 5 genes	GRCh37/hg19 3q26.31(chr3:172003745-172520446)x3	CN GAIN	Uncertain Significance	221435		GRCh37: 3:172003745-172520446 GRCh38:
32	overlap with 24 genes	chr19:44501518-45322744 complex variant	COMPLEX	Uncertain Significance	221352		GRCh37: 19:44501518-45322744 GRCh38:
33	overlap with 7 genes	GRCh38/hg38 16q12.1(chr16:47497444-48230506)x1	CN LOSS	Uncertain Significance	221521		GRCh37: 16:47531355-48264417 GRCh38: 16:47497444-48230506
34	overlap with 6 genes	GRCh37/hg19 7q11.23(chr7:73122969-73256410)x3	CN GAIN	Uncertain Significance	221461		GRCh37: 7:73122969-73256410 GRCh38:
35	overlap with 3 genes	GRCh37/hg19 6p21.33(chr6:30698482-30853003)x3	CN GAIN	Uncertain Significance	221455		GRCh37: 6:30698482-30853003 GRCh38:
36	overlap with 27 genes	GRCh38/hg38 17p13.1-12(chr17:9701182-11983353)x1	CN LOSS	Uncertain Significance	221395		GRCh37: 17:9604499-11886670 GRCh38: 17:9701182-11983353
37	LRAT	NM_004744.5(LRAT):c.78T>A (p.Ser26Arg)	SNV	Uncertain Significance	221315	rs869025235	GRCh37: 4:155665556-155665556 GRCh38: 4:154744404-154744404
38	overlap with 7 genes	GRCh37/hg19 19q13.12(chr19:36227660-36250792)x3	CN GAIN	Uncertain Significance	221541		GRCh37: 19:36227660-36250792 GRCh38:
39	overlap with 5 genes	GRCh37/hg19 11q23.1(chr11:111735939-111784393)x3	CN GAIN	Uncertain Significance	221481		GRCh37: 11:111735939-111784393 GRCh38:
40	overlap with 20 genes	GRCh37/hg19 19q13.12(chr19:35516999-35990896)x3	CN GAIN	Uncertain Significance	221398		GRCh37: 19:35516999-35990896 GRCh38:
41	overlap with 3 genes	GRCh37/hg19 22q13.33(chr22:50318056-50437748)x3	CN GAIN	Uncertain Significance	221550		GRCh37: 22:50318056-50437748 GRCh38:
42	overlap with 6 genes	GRCh37/hg19 8q22.2(chr8:100871620-101253185)x3	CN GAIN	Uncertain Significance	221467		GRCh37: 8:100871620-101253185 GRCh38:
43	PHF24	NM_015297.3(PHF24):c.242G>A (p.Arg81Gln)	SNV	Uncertain Significance	221301	rs374394658	GRCh37: 9:34971537-34971537 GRCh38: 9:34971540-34971540
44	overlap with 6 genes	GRCh38/hg38 21q22.3(chr21:45850091-46137287)x1	CN LOSS	Uncertain Significance	221407		GRCh37: 21:47270005-47557201 GRCh38: 21:45850091-46137287
45	overlap with 5 genes	chr1:16902894-17264939 complex variant	COMPLEX	Uncertain Significance	221358		GRCh37: 1:16902894-17264939 GRCh38:
46	NTS	NM_006183.5(NTS):c.185G>A (p.Cys62Tyr)	SNV	Uncertain Significance	221327	rs869025243	GRCh37: 12:86272172-86272172 GRCh38: 12:85878394-85878394
47	overlap with 3 genes	GRCh37/hg19 2q31.3-32.1(chr2:182756899-183051256)x4	CN GAIN	Uncertain Significance	221427		GRCh37: 2:182756899-183051256 GRCh38:
48	MICAL2	NM_001282663.2(MICAL2):c.3131A>G (p.Asp1044Gly)	SNV	Uncertain Significance	221304	rs869025227	GRCh37: 11:12278507-12278507 GRCh38: 11:12256960-12256960
49	TUBA3E	chr2:130949553-130952725 complex variant	COMPLEX	Uncertain Significance	221361		GRCh37: 2:130949553-130952725 GRCh38:
50	UNC45A and overlap with 1 gene(s)	GRCh37/hg19 15q26.1(chr15:91475054-91478581)x3	CN GAIN	Uncertain Significance	221504		GRCh37: 15:91475054-91478581 GRCh38:

Cosmic variations for Breast Ductal Carcinoma:

⁸ (show top 50) (show all 14495)

#	Cosmic Mut ID	Gene Symbol	COSMIC Disease Classification (Primary site, Site subtype, Primary histology, Histology subtype)	Mutation CDS	Mutation AA	GRCh38 Location	Conf
1	COSM103978702	ZSWIM8	breast,NS,carcinoma,ductal carcinoma	c.3423G>A	p.K1141=	10:73797261-73797261	15
2	COSM143704807	ZSWIM8	breast,NS,carcinoma,ductal carcinoma	c.3408G>A	p.K1136=	10:73797261-73797261	15
3	COSM143340021	ZSWIM8	breast,NS,carcinoma,ductal carcinoma	c.3423G>A	p.K1141=	10:73797261-73797261	15
4	COSM143155659	ZSWIM8	breast,NS,carcinoma,ductal carcinoma	c.3408G>A	p.K1136=	10:73797261-73797261	15
5	COSM141577245	ZSWIM8	breast,NS,carcinoma,ductal carcinoma	c.3309G>A	p.K1103=	10:73797261-73797261	15
6	COSM88263804	ZRSR2	breast,NS,carcinoma,ductal carcinoma	c.1084G>A	p.E362K	23:15822877-15822877	15
7	COSM88263027	ZRSR2	breast,NS,carcinoma,ductal carcinoma	c.1406C>T	p.S469L	23:15823199-15823199	15
8	COSM88262392	ZRSR2	breast,NS,carcinoma,ductal carcinoma	c.1312G>T	p.G438C	23:15823105-15823105	15
9	COSM88264460	ZRSR2	breast,NS,carcinoma,ductal carcinoma	c.267G>C	p.K89N	23:15803751-15803751	15
10	COSM88263630	ZRSR2	breast,NS,carcinoma,ductal carcinoma	c.989A>G	p.H330R	23:15822782-15822782	15
11	COSM90724063	ZNHIT2	breast,NS,carcinoma,ductal carcinoma	c.175G>C	p.A59P	11:65117479-65117479	15
12	COSM96875678	ZNF830	breast,NS,carcinoma,ductal carcinoma	c.136A>G	p.N46D	17:34961702-34961702	15
13	COSM101741828	ZNF668	breast,NS,carcinoma,ductal carcinoma	c.856G>A	p.G286S	16:31062072-31062072	15
14	COSM133260197	ZNF668	breast,NS,carcinoma,ductal carcinoma	c.856G>A	p.G286S	16:31062072-31062072	15
15	COSM133259918	ZNF668	breast,NS,carcinoma,ductal carcinoma	c.196G>A	p.A66T	16:31064264-31064264	15
16	COSM101741790	ZNF668	breast,NS,carcinoma,ductal carcinoma	c.992C>G	p.T331R	16:31061936-31061936	15
17	COSM131594768	ZNF668	breast,NS,carcinoma,ductal carcinoma	c.925G>A	p.G309S	16:31062072-31062072	15
18	COSM87497387	ZNF668	breast,NS,carcinoma,ductal carcinoma	c.196G>A	p.A66T	16:31064264-31064264	15
19	COSM87497658	ZNF668	breast,NS,carcinoma,ductal carcinoma	c.856G>A	p.G286S	16:31062072-31062072	15
20	COSM132355503	ZNF668	breast,NS,carcinoma,ductal carcinoma	c.992C>G	p.T331R	16:31061936-31061936	15
21	COSM132355522	ZNF668	breast,NS,carcinoma,ductal carcinoma	c.856G>A	p.G286S	16:31062072-31062072	15
22	COSM131594485	ZNF668	breast,NS,carcinoma,ductal carcinoma	c.265G>A	p.A89T	16:31064264-31064264	15
23	COSM131594753	ZNF668	breast,NS,carcinoma,ductal carcinoma	c.1061C>G	p.T354R	16:31061936-31061936	15
24	COSM132355306	ZNF668	breast,NS,carcinoma,ductal carcinoma	c.196G>A	p.A66T	16:31064264-31064264	15
25	COSM108404990	ZNF668	breast,NS,carcinoma,ductal carcinoma	c.265G>A	p.A89T	16:31064264-31064264	15
26	COSM101741584	ZNF668	breast,NS,carcinoma,ductal carcinoma	c.196G>A	p.A66T	16:31064264-31064264	15
27	COSM133260145	ZNF668	breast,NS,carcinoma,ductal carcinoma	c.992C>G	p.T331R	16:31061936-31061936	15
28	COSM108405155	ZNF668	breast,NS,carcinoma,ductal carcinoma	c.1061C>G	p.T354R	16:31061936-31061936	15
29	COSM87497622	ZNF668	breast,NS,carcinoma,ductal carcinoma	c.992C>G	p.T331R	16:31061936-31061936	15
30	COSM108405172	ZNF668	breast,NS,carcinoma,ductal carcinoma	c.925G>A	p.G309S	16:31062072-31062072	15
31	COSM87511923	ZNF646	breast,NS,carcinoma,ductal carcinoma	c.4010A>T	p.N1337I	16:31080334-31080334	15
32	COSM101729269	ZNF646	breast,NS,carcinoma,ductal carcinoma	c.4010A>T	p.N1337I	16:31080334-31080334	15
33	COSM92054903	ZNF644	breast,NS,carcinoma,ductal carcinoma	c.23-23043G>C	p.?	1:90941197-90941197	15
34	COSM95319541	ZNF644	breast,NS,carcinoma,ductal carcinoma	c.157G>C	p.E53Q	1:90941197-90941197	15
35	COSM94049964	ZNF644	breast,NS,carcinoma,ductal carcinoma	c.23-23043G>C	p.?	1:90941197-90941197	15
36	COSM91884936	ZNF644	breast,NS,carcinoma,ductal carcinoma	c.157G>C	p.E53Q	1:90941197-90941197	15
37	COSM139305666	ZNF569	breast,NS,carcinoma,ductal carcinoma	c.157C>G	p.Q53E	19:37426309-37426309	15
38	COSM91675445	ZNF569	breast,NS,carcinoma,ductal carcinoma	c.85C>G	p.Q29E	19:37426309-37426309	15
39	COSM100881762	ZNF569	breast,NS,carcinoma,ductal carcinoma	c.85C>G	p.Q29E	19:37426309-37426309	15
40	COSM100886533	ZNF569	breast,NS,carcinoma,ductal carcinoma	c.-239-11890C>G	p.?	19:37426309-37426309	15
41	COSM139323876	ZNF569	breast,NS,carcinoma,ductal carcinoma	c.16-11890C>G	p.?	19:37426309-37426309	15
42	COSM90464551	ZNF548	breast,NS,carcinoma,ductal carcinoma	c.70G>T	p.D24Y	19:57397066-57397066	15
43	COSM139958759	ZNF548	breast,NS,carcinoma,ductal carcinoma	c.70G>T	p.D24Y	19:57397066-57397066	15
44	COSM93683315	ZNF548	breast,NS,carcinoma,ductal carcinoma	c.34G>T	p.D12Y	19:57397066-57397066	15
45	COSM140877756	ZNF548	breast,NS,carcinoma,ductal carcinoma	c.70G>T	p.D24Y	19:57397066-57397066	15
46	COSM141497466	ZNF532	breast,NS,carcinoma,ductal carcinoma	c.2465C>T	p.S822L	18:58934551-58934551	15
47	COSM90396499	ZNF532	breast,NS,carcinoma,ductal carcinoma	c.2465C>T	p.S822L	18:58934551-58934551	15
48	COSM141373096	ZNF532	breast,NS,carcinoma,ductal carcinoma	c.2465C>T	p.S822L	18:58934551-58934551	15
49	COSM139185737	ZNF532	breast,NS,carcinoma,ductal carcinoma	c.2465C>T	p.S822L	18:58934551-58934551	15
50	COSM139904572	ZNF532	breast,NS,carcinoma,ductal carcinoma	c.2465C>T	p.S822L	18:58934551-58934551	15

Copy number variations for Breast Ductal Carcinoma from CNVD:

⁶ (show all 33)

#	CNVD ID	Chromosome	Start	End	Type	Gene Symbol	CNVD Disease
1	50888	11	119630000	120260000	Deletion		Ductal carcinoma
2	57116	11	63100000	76700000	Amplification	CCND1	Ductal carcinoma
3	58629	11	68930000	70160000	Gain		Ductal carcinoma
4	58724	11	69230000	69780000	Gain		Ductal carcinoma
5	59882	11	78860000	79330000	Deletion		Ductal carcinoma
6	60225	11	84000000	88080000	Deletion		Ductal carcinoma
7	60766	11	91240000	95940000	Deletion		Ductal carcinoma
8	66468	12	2966849	2986303	Copy number	FOXM1	Ductal carcinoma
9	98103	16	15360000	17700000	Gain		Ductal carcinoma
10	99317	16	25030000	27880000	Gain		Ductal carcinoma
11	101507	16	40000	40090000	Gain		Ductal carcinoma
12	107663	17	16530000	18020000	Deletion		Ductal carcinoma
13	109740	17	28800000	35400000	Amplification	ERBB2	Ductal carcinoma
14	116392	17	6500000	10700000	Copy number	TP53	Ductal carcinoma
15	117043	17	70920000	72340000	Gain		Ductal carcinoma
16	126771	19	20810000	63790000	Gain		Ductal carcinoma
17	127047	19	23780000	51950000	Gain		Ductal carcinoma
18	128079	19	39420000	40350000	Gain		Ductal carcinoma
19	131070	19	52760000	63790000	Gain		Ductal carcinoma
20	153161	20	34860000	62370000	Gain		Ductal carcinoma
21	153748	20	41100000	62435964	Amplification	BMP7	Ductal carcinoma
22	166731	3	107740000	107880000	Deletion		Ductal carcinoma
23	166830	3	108620000	110660000	Deletion		Ductal carcinoma
24	167069	3	112930000	115910000	Deletion		Ductal carcinoma
25	179845	3	99790000	104540000	Deletion		Ductal carcinoma
26	196641	5	170120000	170210000	Gain		Ductal carcinoma
27	196700	5	170690000	172750000	Gain		Ductal carcinoma
28	215548	6	77380000	82650000	Deletion		Ductal carcinoma
29	231989	8	110000	5150000	Deletion		Ductal carcinoma
30	233354	8	124380000	129070000	Gain		Ductal carcinoma
31	234986	8	140450000	141700000	Gain		Ductal carcinoma
32	238072	8	29700000	38500000	Amplification	FGFR1	Ductal carcinoma
33	239766	8	41480000	42480000	Gain		Ductal carcinoma

Sources

Expression for Breast Ductal Carcinoma

Search GEO for disease gene expression data for Breast Ductal Carcinoma.

Sources

Pathways for Breast Ductal Carcinoma

Pathways related to Breast Ductal Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 75)

#	Super pathways	Score	Top Affiliating Genes
1	Signal Transduction ⁶⁶	13.75	BCL2 CCND1 CDH1 CTNNB1 CTSD EGFR
2	ERK Signaling ⁶⁴ Show member pathways ILK Signaling ⁶⁴ MAPK Signaling ⁶⁴ Molecular Mechanisms of Cancer ⁶⁴ Rho Family GTPases ⁶⁴	13.74	BCL2 BRCA1 CCND1 CDH1 CDH3 CTNNB1
3	GPCR Pathway ⁶⁴ Show member pathways Breast Cancer Regulation by Stathmin1 ⁶⁴ Estrogen Pathway ⁶⁴ NFAT in Immune Response ⁶⁴ P2Y Receptor Signaling ⁶⁴ Pancreatic Adenocarcinoma ⁶⁴ Paxillin Interactions ⁶⁴ Ras Pathway ⁶⁴	13.72	VEGFD TP53 ESR1 ERBB2 EGFR CCND1
4	Akt Signaling ⁶⁴ Show member pathways p38 Signaling ⁶⁴ Tec Kinases Signaling ⁶⁴	13.44	BCL2 CCND1 EGFR ERBB2 PIP TP53
5	PAK Pathway ⁶⁴ Show member pathways Antioxidant Action of Vitamin-C ⁶⁴ Epithelial Adherens Junctions ⁶⁴	13.33	BCL2 CDH1 CTNNB1 EGFR ERBB2 PIP
6	Nanog in Mammalian ESC Pluripotency ⁶⁴ Show member pathways 14-3-3 Induced Intracellular Signaling ⁶⁴ eNOS Signaling ⁶⁴ GSK3 Signaling ⁶⁴	13.31	VEGFD ESR1 ERBB2 EGFR CTNNB1 CDH3
7	ESR-mediated signaling ⁶⁶ Show member pathways Estrogen-dependent gene expression ⁶⁶ RUNX1 regulates estrogen receptor mediated transcription ⁶⁶ Signaling by Nuclear Receptors ⁶⁶	13	BCL2 CCND1 CTSD EGFR ESR1 PGR
8	PI3K-Akt signaling pathway ⁷⁴ Show member pathways Focal adhesion: PI3K-Akt-mTOR-signaling pathway ⁷⁴	12.99	VEGFD TP53 EGFR CCND1 BRCA1 BCL2
9	Signaling by Receptor Tyrosine Kinases ⁶⁶	12.84	VEGFD PGR ESR1 ERBB2 EGFR CTSD
10	Endometrial cancer ⁷⁴ Show member pathways Chromosomal and microsatellite instability in colorectal cancer ⁷⁴ Melanoma ⁷⁴ Non-small cell lung cancer ⁷⁴ Pancreatic adenocarcinoma pathway ⁷⁴ Signal transduction PTEN pathway ²²	12.69	BCL2 CCND1 CDH1 CTNNB1 EGFR ERBB2
11	Chks in Checkpoint Regulation ⁶⁴ Show member pathways DNA Repair Mechanisms ⁶⁴ Estrogen-mediated S-Phase Entry ⁶⁴ G2-M Phase Transition ⁶⁴ SREBP Proteolysis ⁶⁴	12.64	TP53 ESR1 CCND1 BRCA1 BCL2
12	Immune response IL-23 signaling pathway ²² Show member pathways Angiopoietin receptor Tie2-mediated signaling ⁶¹ Angiopoietin-TIE2 Signaling ⁶⁴ Development Angiopoietin - Tie2 signaling ²² Development PDGF signaling via STATs and NF-kB ²² IL23-mediated signaling events ⁶¹ Immune response IL-10 signaling pathway ²² RAC1/PAK1/p38/MMP2 pathway ⁷⁴	12.62	TP53 ERBB2 EGFR CTNNB1 BCL2
13	Malignant pleural mesothelioma ⁷⁴	12.58	VEGFD TP53 EGFR CTNNB1 CDH1 CCND1
14	DNA Damage ³	12.54	BRCA1 CCND1 MKI67 RAD54L TP53
15	Development EGFR signaling pathway ²² Show member pathways Development ERBB-family signaling ²² EGF Pathway ⁶⁴ EGFR Signaling Pathway ⁶⁷ ErbB receptor signaling network ⁶¹	12.52	TP53 ERBB2 EGFR CTNNB1 CDH1
16	WNT Signaling ⁶⁴	12.45	TP53 CTNNB1 CDH3 CDH1 CCND1
17	NF-kappaB Pathway ⁷⁰ Show member pathways Akt Pathway ⁷⁰ Apoptosis Pathway ⁷⁰	12.45	TP53 ERBB2 EGFR CTNNB1 BCL2
18	Development Dopamine D2 receptor transactivation of EGFR ²² Show member pathways Chemotaxis CXCR4 signaling pathway ²² Development Alpha-2 adrenergic receptor activation of ERK ²² Extra-nuclear estrogen signaling ⁶⁶	12.44	ESR1 EGFR CCND1 BCL2
19	G-protein signaling RAC1 in cellular process ²² Show member pathways CDC42 signaling events ⁶¹ Cytoskeleton remodeling CDC42 in cellular processes ²² RAC1 signaling pathway ⁶¹	12.42	VEGFD ERBB2 EGFR CTNNB1 CDH1
20	Hepatocyte growth factor receptor signaling ⁷⁴ Show member pathways Apoptosis and survival Anti-apoptotic action of membrane-bound ESR1 ²² Apoptosis and survival NGF signaling pathway ²² Apoptosis and survival Role of CDK5 in neuronal death and survival ²² Development HGF signaling pathway ²² Development Neurotrophin family signaling ²² Drug-mediated inhibition of MET activation ⁶⁶ MET activates PTPN11 ⁶⁶ MET activates STAT3 ⁶⁶ PLC-gamma1 signalling ⁶⁶ Trk receptor signaling mediated by PI3K and PLC-gamma ⁶¹ TRKA activation by NGF ⁶⁶	12.41	TP53 ESR1 ERBB2 CTNNB1 CDH1 CCND1
21	Cell cycle Regulation of G1/S transition (part 1) ²² Show member pathways Cell cycle ESR1 regulation of G1/S transition ²² Cell cycle Role of SCF complex in cell cycle regulation ²² Immune response MIF-JAB1 signaling ²² Mitotic Roles of Polo Like Kinases ⁶⁴	12.4	PGR ESR1 CCND1 BRCA1
22	Development Ligand-independent activation of ESR1 and ESR2 ²² Show member pathways Transcription CREB pathway ²² Transcription PPAR Pathway ²²	12.35	TFF1 ESR1 ERBB2 EGFR CCND1
23	p53 Signaling ⁶⁴ Show member pathways p53 Pathway ⁶⁷	12.25	BCL2 BRCA1 CCND1 TP53
24	Focal adhesion ⁷⁴	12.25	VEGFD ERBB2 EGFR CTNNB1 CCND1 BCL2
25	MAPK Signaling: Mitogens ⁶⁵ Show member pathways Akt Signaling Pathway ⁶⁵	12.24	TP53 ERBB2 EGFR CCND1 BCL2
26	Colorectal Cancer Metastasis ⁶⁴	12.21	TP53 EGFR CTNNB1 CDH1 CCND1
27	Breast cancer pathway ⁷⁴ Show member pathways Embryonic stem cell pluripotency pathways ⁷⁴	12.19	BRCA1 CCND1 CTNNB1 EGFR ERBB2 ESR1
28	Transcription Androgen Receptor nuclear signaling ²² Show member pathways Translation Non-genomic (rapid) action of Androgen Receptor ²²	12.16	ERBB2 EGFR CTNNB1 CCND1
29	Presenilin-Mediated Signaling ⁶⁴	12.14	CTNNB1 CDH3 CDH1 BCL2
30	Signaling by ERBB4 ⁶⁶ Show member pathways Downregulation of ERBB4 signaling ⁶⁶ ErbB4 signaling events ⁶¹ Nuclear signaling by ERBB4 ⁶⁶	12.1	PGR ESR1 ERBB2 EGFR
31	Direct p53 effectors ⁶¹	12.08	TP53 EGFR CTSD BCL2
32	Adhesion ³	12.05	TFF1 CTNNB1 CDH3 CDH1
33	Gastrin signaling pathway ⁷⁴	12	CCND1 CDH1 CTNNB1 EGFR
34	DNA damage response (only ATM dependent) ⁷⁴	11.92	TP53 ERBB2 CTNNB1 CCND1 BCL2
35	Small cell lung cancer ⁷⁴	11.91	TP53 CCND1 BCL2
36	Hippo-Merlin signaling dysregulation ⁷⁴ Show member pathways Hippo signaling regulation pathways ⁷⁴	11.88	EGFR CTNNB1 CCND1
37	Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors ⁶⁶ Show member pathways Activation of the TFAP2 (AP-2) family of transcription factors ⁶⁶ Negative regulation of activity of TFAP2 (AP-2) family transcription factors ⁶⁶ TFAP2 (AP-2) family regulates transcription of cell cycle factors ⁶⁶ TFAP2 (AP-2) family regulates transcription of growth factors and their receptors ⁶⁶ TFAP2 (AP-2) family regulates transcription of other transcription factors ⁶⁶ TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation ⁶⁶	11.87	ESR1 ERBB2 EGFR
38	Acute viral myocarditis ⁷⁴	11.79	KRT8 CCND1 BCL2
39	Regulation of nuclear beta catenin signaling and target gene transcription ⁶¹	11.77	CTNNB1 CDH1 CCND1
40	Primary focal segmental glomerulosclerosis (FSGS) ⁷⁴	11.77	MKI67 KRT8 CTNNB1
41	Transcription Ligand-dependent activation of the ESR1/SP pathway ²² Show member pathways Development Ligand-dependent activation of the ESR1/AP-1 pathway ²²	11.76	CCND1 EGFR ESR1
42	AP-1 transcription factor network ⁶¹	11.76	TP53 ESR1 CTNNB1 CCND1
43	Regulation of Telomerase ⁶¹	11.74	ESR1 EGFR CCND1
44	Physico-chemical features and toxicity-associated pathways ⁷⁴	11.72	ERBB2 EGFR CTNNB1
45	Head and neck squamous cell carcinoma ⁷⁴	11.72	TP53 ERBB2 EGFR CTNNB1 CCND1
46	Pathways affected in adenoid cystic carcinoma ⁷⁴	11.7	TP53 ERBB2 BRCA1
47	Validated targets of C-MYC transcriptional repression ⁶¹	11.7	ERBB2 CCND1 BRCA1 BCL2
48	Coregulation of Androgen receptor activity ⁶¹	11.69	CTNNB1 CCND1 BRCA1
49	ATF-2 transcription factor network ⁶¹	11.65	BCL2 BRCA1 CCND1 ESR1
50	Hepatitis C and hepatocellular carcinoma ⁷⁴	11.64	TP53 CCND1 BRCA1

Sources

GO Terms for Breast Ductal Carcinoma

Cellular components related to Breast Ductal Carcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	protein-containing complex	GO:0032991	9.8	TP53 RAD54L ESR1 EGFR CTNNB1 BRCA1
2	catenin complex	GO:0016342	9.1	CTNNB1 CDH3 CDH1

Biological processes related to Breast Ductal Carcinoma according to GeneCards Suite gene sharing:

(show all 15)

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of gene expression	GO:0010628	10.13	BRCA1 CDH3 CTNNB1 ERBB2 PGR PIP
2	cell-cell adhesion	GO:0098609	10.06	EGFR CTNNB1 CDH3 CDH1 BCL2
3	T cell differentiation in thymus	GO:0033077	9.99	TP53 CTNNB1 BCL2
4	fibroblast proliferation	GO:0048144	9.93	ESR1 TP53 VEGFD
5	negative regulation of reactive oxygen species metabolic process	GO:2000378	9.85	TP53 BRCA1 BCL2
6	positive regulation of RNA polymerase II transcription preinitiation complex assembly	GO:0045899	9.8	TP53 ESR1
7	B cell lineage commitment	GO:0002326	9.78	TP53 BCL2
8	response to xenobiotic stimulus	GO:0009410	9.77	BCL2 CCND1 CDH1 CDH3 CTNNB1 RAD54L
9	response to UV-A	GO:0070141	9.73	EGFR CCND1
10	response to iron ion	GO:0010039	9.73	TFF1 CCND1 BCL2
11	hair cycle process	GO:0022405	9.71	CTNNB1 CDH3
12	T cell lineage commitment	GO:0002360	9.7	TP53 BCL2
13	cellular response to indole-3-methanol	GO:0071681	9.63	CTNNB1 CDH1 BRCA1
14	positive regulation of miRNA maturation	GO:1903800	9.55	TP53 EGFR
15	cell population proliferation	GO:0008283	9.28	TP53 TFF1 MKI67 EGFR CTNNB1 CCND1

Molecular functions related to Breast Ductal Carcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	identical protein binding	GO:0042802	10.2	BCL2 BRCA1 CDH1 EGFR ERBB2 ESR1
2	enzyme binding	GO:0019899	9.8	TP53 PGR ESR1 EGFR CTNNB1 CCND1
3	ATP-dependent DNA/DNA annealing activity	GO:0036310	9.56	TP53 RAD54L
4	protein phosphatase binding	GO:0019903	9.28	TP53 ERBB2 EGFR CTNNB1 BCL2